Regulation FD Disclosure (Form 8-K)

On December 19, 2025, Cytokinetics, Incorporated ("Cytokinetics") announced that the U.S. Food and Drug Administration approved a New Drug Application for MYQORZO (aficamten). MYQORZO is a cardiac myosin inhibitor for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

As part of funding agreements with Cytokinetics in January 2022 and May 2024, Royalty Pharma is entitled to a royalty of 4.5% on MYQORZO sales up to $5 billion, decreasing to 1% on sales above $5 billion.

Additionally, in 2022, Royalty Pharma provided Cytokinetics long-term capital of up to $225 million related to MYQORZO, all of which has been drawn. In 2024, Royalty Pharma provided Cytokinetics additional launch capital of up to $225 million, of which $50 million has been drawn. Based on the amount drawn to date, Royalty Pharma will receive $523 million in quarterly repayments over 10 years (1.9x the total amount drawn), of which $20 million has been repaid through September 30, 2025.

Following MYQORZO approval, Cytokinetics is also eligible to draw an additional $175 million within the next 12 months. Royalty Pharma will receive 1.9x the total amount drawn payable over 10 years in quarterly installments.